- Open Access
Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels
© Murgai et al.; licensee BioMed Central Ltd. 2013
- Received: 27 November 2012
- Accepted: 7 March 2013
- Published: 27 March 2013
Xenotropic Murine leukemia virus-Related Virus (XMRV) is a γ-retrovirus initially reported to be present within familial human prostate tumors and the blood of patients with chronic fatigue syndrome. Subsequent studies however were unable to replicate these findings, and there is now compelling evidence that the virus evolved through rare retroviral recombination events in human tumor cell lines established through murine xenograft experiments. There is also no direct evidence that XMRV infection has any functional effects that contribute to tumor pathogenesis.
Herein we describe an additional xenotropic MLV, “B4rv”, found in a cell line derived from xenograft experiments with the human prostate cancer LNCaP cell line. When injected subcutaneously in nude mice, LNCaP cells infected with XMRV or B4rv formed larger tumors that were highly hemorrhagic and displayed poor pericyte/smooth muscle cell (SMC) investment, markers of increased metastatic potential. Conditioned media derived from XMRV- or B4rv-infected LNCaPs, but not an amphotropic MLV control virus infected LNCaPs, profoundly decreased expression of marker genes in cultured SMC, consistent with inhibition of SMC differentiation/maturation. Similar effects were seen with a chimeric virus of the amphotropic MLV control virus containing the XMRV env gene, but not with an XMRV chimeric virus containing the amphotropic MLV env gene. UV-inactivated XMRV and pseudovirions that were pseudotyped with XMRV envelope protein also produce conditioned media that down-regulated SMC marker gene expression in vitro.
Together these results indicate that xenotropic MLV envelope proteins are sufficient to induce the production of factors by tumor cells that suppress vascular SMC differentiation, providing evidence for a novel mechanism by which xenotropic MLVs might alter tumor pathogenesis by disrupting tumor vascular maturation. Although it is highly unlikely that either XMRV or B4Rv themselves infect humans and are pathogenic, the results suggest that xenograft approaches commonly used in the study of human cancer promote the evolution of novel retroviruses with pathogenic properties.
- Chronic Fatigue Syndrome
- LNCaP Cell
- Vascular SMCs
- Xenograft Experiment
- Prostate Cancer LNCaP Cell Line
Xenotropic Murine leukemia virus-Related Virus (XMRV) is a γ-retrovirus that was initially reported as present in human prostate tumors from patients with RNaseL inactivating polymorphisms [1–3] and in the blood of patients with chronic fatigue syndrome [2, 4]. However, recent studies were unable to replicate these results [5–9]. A recent study by one of our laboratories , demonstrated that XMRV likely arose through recombination of two murine endogenous proviruses, named PreXMRV-1 and PreXMRV-2, as a consequence of xenograft experiments involving implantation of human tumor cells into nude mice followed by selection based on desired tumorigenic phenotypes including androgen independence, rapid anchorage-independent growth, and other properties. It now appears very likely that detection of XMRV in human tissues represented laboratory contamination and/or faulty PCR methodology [11–13].
The evidence that XMRV was generated as a consequence of studies aimed at elucidating the pathology of human disease is disturbing in that it highlights long feared dangers of use of xenograft tissues in clinical settings, including porcine valves [14, 15]. Of even greater concern, the results support the idea that attempts to develop better therapeutic interventions might inadvertently promote the development of pathogenic viruses. However, the following observations refute this possibility: First, although xenotropic and polytropic MLVs have been described as far back as 1970 [16, 17], as of yet there has been no validated evidence of human infection by this class of viruses. Second, despite intensive investigation of XMRV by many laboratories [1, 18, 19] there is no evidence that XMRV is capable of inducing transformation of cells [1, 20], although there is recent evidence showing that XMRV infection of LNCaP cells resulted in modest increases in proliferation, and invasion of cells into Matrigel in vitro (Pandhare-Dash et al.[4, 21]). Consistent with these findings, Stieler et al.[5, 22, 23] showed that shRNA-induced suppression of XMRV particle production reduced migration and the secretion of cytokines including osteopontin, CXCL14, IL13, and TIMP2 in the human prostate tumor cell line 22Rv1 in vitro, and resulted in decreased angiogenesis, reduced tumor size, and increased necrosis when cells were implanted in nude mice in vivo. Whether these differences can be directly ascribed to XMRV warrants further investigation, as this study does not compare these results to an uninfected cancer cell line control and nor identify how XMRV might induce functional changes.
Nevertheless, these results are of considerable interest since they suggest that infection of tumor cells with XMRV induces multiple changes that could possibly impact tumor pathogenicity, although presumably only in an experimental setting since there is no evidence it is capable of infecting human cells other than in vitro or in a xenograft. Given the remarkable plasticity of retroviruses, and the widespread use of xenograft approaches in the study of cancer, there are a number of critical unresolved questions: 1) While the combination of events that led to derivation of XMRV are extraordinarily rare [10, 24, 25], do similar XMRV-like viruses exist in other xenograft-derived cell lines due to selection processes common in these sorts of experiments? 2) Does XMRV infection of tumor cells impact tumorigenicity in vivo? 3) What are the mechanisms by which XMRV or XMRV gene products alter the functional properties of tumor cells in ways that may impact tumor pathogenesis? The studies described herein address these questions, and show that at least one other XMRV-like virus exists, and that the virus evolved the ability to infect human cells and to express gene products that impact tumor pathogenesis.
Identification of an independent XMRV-like retrovirus derived from a mouse-human xenograft-derived prostate tumor cell line
XMRV- or B4rv-infected subcutaneous tumors were larger and exhibited defective vascular maturation
To determine mechanisms by which infection with XMRV and B4rv might increase tumor growth, we first tested if there were effects on proliferation or apoptosis. Staining and quantification of Ki-67 positive nuclei demonstrated no significant change in proliferation between tumors that resulted from XMRV- or B4rv-infected LNCaPs, and uninfected LNCaP tumors (Additional file 2: Figures S2a, c). These results were confirmed via in vitro cell counts (Additional file 2: Figure S2b). Staining of tumor sections for cleaved caspase-3 revealed a statistically significant increase in apoptotic cells within tumors derived from XMRV- or B4rv-infected LNCaP tumors as compared to uninfected or 4070a-infected LNCaP tumors (Additional file 3: Figure S3). As such, the observed increase in diameter of tumors with XMRV- or B4rv-infected LNCaP cells is not a direct function of a reduced apoptotic rate of tumor cells, although it is possible that the observed increase in apoptosis may contribute to tumor pathogenesis indirectly through generation of apoptotic products, and associated immune cell responses. Taken together, results indicate that the observed increases in size of XMRV- or B4rv-infected LNCaP tumors was not due to changes in the rate of tumor cell proliferation or apoptosis, thus implicating alternative mechanisms.
By gross examination, XMRV- or B4rv-infected LNCaP tumors appeared highly vascularized and hemorrhagic appearing nearly black at the surface of the tumor due to loss of blood into the interstitium (Figure 2B, Additional file 1: Figure S1f), suggesting that infection with these MLV viruses may have induced increased angiogenesis and defects in blood vessel maturation. We confirmed these findings by confocal analysis where staining with isolectin for endothelial cells, SM alpha-actin (Acta2) for vascular SMCs (Figure 2C) and NG2 for pericytes (Additional file 4: Figure S4, Additional file 5: Figure S5, Additional file 6: Figure S6, Additional file 7: Figure S7) showed an increase in vessel density (Additional file 1: Figure S1e) and a decrease in SMC and pericyte association with endothelial cells (Figure 2D, Additional file 1: Figure S1e). Staining for TER-119 for red blood cells and SM alpha-actin for SMCs (Figure 2E) showed a marked increase in hemorrhage, calculated as the percent of positive staining found outside of blood vessels (Figure 2F). Taken together, these results suggest that the increased size of XMRV- or B4rv-infected LNCaP tumors may be due at least in part to vascular leakage and deposition of blood products within the tumor stroma.
B4rv- or XMRV-infected LNCaP cells secrete factors that promote HUVEC tube formation but inhibit differentiation of vascular SMCs in vitro
XMRV envelope proteins mediate inhibition of differentiation in vascular SMCs
To determine if viral gene expression is necessary to confer this phenotype, we exposed XMRV or MoMLV-4070a viral particles to UV irradiation prior to applying them on LNCaP cells to generate TCM. Although only 10 minutes of exposure to UV irradiation was needed to ablate the infectivity of either virus (Additional file 9: Figure S9e), the TCM of LNCaPs exposed to XMRV viral particles that were UV irradiated for 10 minutes suppressed SMC marker gene expression, with no significant difference when compared to the TCM of LNCaPs infected with XMRV not exposed to UV irradiation (Figure 4B). TCM from LNCaPs exposed to MoMLV-4070a viral particles that were irradiated at any dose was unable to suppress SMC marker gene expression, just as was observed using TCM from LNCaPs infected with MoMLV-4070a that was not irradiated.
To further explore whether the presence of xenotropic MLV envelope proteins at the cell surface was sufficient to confer this phenotype, we generated XMRV pseudotyped MoMLV viral particles that were only capable of expressing GFP, and not any retroviral genes (Additional file 9: Figure S9d). In addition, PreXMRV-1-pseudotyped MoMLV viral particles were also produced and included in this experiment due to the sequence similarity of this proviral sequence to B4rv in the env gene (Figure 1A). TCM from LNCaP cells exposed to XMRV or PreXMRV1 pseudotyped viral particles, but not from LNCaP cells exposed to viral particles pseudotyped with an amphotropic MLV envelope, was able to suppress SMC marker gene expression (Figure 4C). Taken together the results of the preceding experiments provide compelling evidence that the env gene products of XMRV and B4rv are sufficient to induce the production of factors by infected tumor cells into conditioned media that modulate SMC marker gene expression. These data suggest that xenotropic MLV envelope proteins assembled on viral particles, independent of other xenotropic MLV genes, induce the production of soluble factors by tumor cells that suppress SMC marker gene expression, resulting in defective blood vessel maturation and increased vessel density.
Our results reveal the presence of a novel xenotropic MLV that, like XMRV, was likely generated through the recombination of endogenous murine proviral sequences via xenograft experiments in nude mice. We postulate that such recombination events may be extremely rare and yet the generation of similar viruses may be enhanced as a consequence of extraordinary selection pressures inherent in typical xenograft and culture experiments. We further show that defective blood vessel formation is a functional consequence of infection by these xenotropic MLVs, resulting in larger tumors that possess greater numbers of blood vessels that are immature and hemorrhagic. Remarkably, our in vitro results indicate that exposure to the xenotropic MLV envelope proteins is sufficient to induce tumor cells to produce factors that alter vascular SMCs to an immature phenotype, suggesting a novel mechanism by which xenotropic viral infection of tumor cells leads to the formation of immature blood vessels.
Disrupted tumor vascular maturation has long been equated with high rates of tumor cell shedding and metastasis [16, 28]. Highly hemorrhagic tumors that contain an abundance of dilated, immature blood vessels poorly invested with vascular SMCs and pericytes exhibit increased metastatic potential [18, 29]. Consistent with this possibility, Ramaswamy et al.[20, 30] used microarray analysis of over 800 human solid tumors and metastases and demonstrated that 4 of the 9 genes whose down-regulation is highly predictive of tumor metastasis encode markers of differentiated SMC/pericytes, suggesting that a lack of differentiated SMC/pericytes within tumor biopsy samples is highly predictive of tumor metastatic potential. Immature vascular networks are also highly inefficient for blood delivery and exhibit impaired delivery of chemotherapeutic agents, resulting in higher levels of agents in normal versus tumor tissues , which is also thought to contribute to the poor overall efficacy of anti-angiogenic therapies due to counteracting effects of combined therapies. The mechanisms that contribute to incomplete maturation of tumor vessels are poorly understood, although it may result in part from a hyper-VEGF state, as supported by studies in both animal models and human clinical trials showing at least partial normalization of vessel structure with anti-VEGF therapies [22, 23].
Although neither XMRV nor B4rv are likely to infect humans and contribute to tumor pathogenesis, our observations that xenotropic MLV envelope proteins induce signalling that results in an immature vascular phenotype provide a novel mechanism by which viral gene products might promote tumor pathogenesis. However, there are a number of key unresolved questions: First, what are the mechanisms by which the XMRV envelope proteins interact with tumor cells? Although the known viral entry receptor XPR1 has been shown to mediate entry of XMRV into some cells [24, 25], there is also recent evidence that XMRV can infect cells that do not express XPR1 . Indeed, we have been unable to inhibit the effects of XMRV envelope protein in suppressing SMC differentiation by siRNA-induced inhibition of XPR1 (Additional file 8: Figure S8e). As such, the effects of XMRV envelope protein observed in the present studies appear to be mediated by a receptor or membrane protein or moiety other than XPR1. Based on our data showing an increase in VEGF-dependent endothelial tube formation in the presence of conditional media from B4rv- or XMRV-infected tumor cells (Figure 3C, Additional file 8: Figure S8d), this receptor might be one of a wide range of cell surface molecules that, when activated, may result in the release of VEGFs. Of interest, our observation that production of soluble factors that repress vascular SMC differentiation persisted in LNCaP cells chronically infected with B4rv or XMRV suggests that the envelope protein receptor may not be down-regulated or de-sensitized despite chronic exposure to ligand, and/or that there are positive feedback mechanisms that result in continual regeneration of receptor. Second, what are the rate-limiting mechanisms that prevent xenotropic and/or polytrophic MLVs from infecting humans? Of significance, productive infection by XMRV or B4rv of human cells in vitro appears to be limited to cells that contain defective defences to retroviruses. Indeed, the prostate cancer LNCaP cell line used herein lacks XMRV-restricting APOBECs  and contains a deletion mutation of one allele of RNaseL , a gene critical in the innate immune response to retroviruses. Inactivating polymorphisms of RNaseL are highly associated with familial prostate cancer in young males, and the hypothesis that such deficiencies in innate immunity leaves one vulnerable to a pathogenic retrovirus was the basis for the study that lead to the discovery of XMRV. Since then, any association of XMRV and human infection has been invalidated. However, a critical question is whether utilization of RNaseL defective tumor cells to generate xenograft derived cell lines might allow for the evolution of retroviruses that ordinarily cannot escape cellular immune defences. Third, how does binding of envelope protein to XPR1 or alternative receptor on tumor cells induce production, and/or release of soluble factors that disrupt tumor vascular maturation?
Signalling through retroviral envelope proteins has been shown in other disease models, notably by the Jaagsiekte sheep retrovirus (JSRV) whose envelope proteins cause ovine pulmonary adenocarcinoma through the activation of multiple signaling pathways including the phosphoinositide-3-OH kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK) signaling cascades, binding/degradation of hyaluronidase 2 (Hyal2), and activation of the RON receptor . Degradation products of Hyal2 in particular have been associated with an increase in angiogenesis in the context of xenograft prostate cancer models, outside of the context of JSRV infection. A recent study reports an increase in pro-angiogenic factors within tumors infected with JSRV, particularly VEGF-C and PDGFR-alpha. However the role of the envelope protein in factor production has yet to be elucidated. Other examples of retroviral envelope induced cellular signaling include the Friend spleen focus-forming virus (SFFV), mouse mammary tumor virus (MMTV), enzootic nasal tumor virus (ENTV), and avian hemangioma retrovirus (AHV), all in which envelope proteins contribute to, or induce, transformation . Although previous work by other labs demonstrates that XMRV does not induce transformation [1–3], no work to date has shown whether xenotropic MLVs as a class may activate signaling pathways that promote a pro-tumorigenic environment through indirect mechanisms, including through inducing the secretion of pro-angiogenic factors. This is especially important to examine given that unlike other MLVs that arise in a more organic fashion, all xenotropic MLVs identified to date have been found in the context of xenograft experiments that establish cell lines in the laboratory setting [2, 31], providing a unique and specific selection on this class of MLV. Indeed, given that XMRV and B4rv evolved independently but elicit very similar functional consequences in tumor cells, it is interesting to speculate that there is a unique aspect to xenograft experiments that selects for retroviruses that induce larger, more hemorrhagic tumors.
In summary, the studies described here have identified a second independent xenograft-derived MLV retrovirus designated B4rv that, like XMRV, has acquired the capability of infecting human tumor cells in vitro. Moreover, we provide novel evidence that infection of tumor cells with either XMRV or B4rv results in tumors that are larger and which exhibit multiple changes consistent with disruption of tumor vascular maturation including decreased perivascular cell coverage, and increased hemorrhage. Although it is extremely unlikely that XMRV or B4rv have, or could infect humans [6–9, 32], results herein raise the possibility that additional XMRV-like viruses may exist, or could evolve, that contain gene sequences that impact tumor pathogenesis, and of greatest concern might also acquire the ability to infect humans.
BALB/cAnNCr-nu /nu male mice were obtained at 6 weeks of age from the NCI Frederick Animal Production Program and were handled according to protocols approved by the UVA Institutional Animal Care and Usage Committee guidelines. Each mouse was subcutaneously injected in both flanks with 1x10^6 cells suspended in a 50/50 mixture of PBS and Matrigel. Tumor growth was measured with calipers once per week post-injection, every 2 days once tumor growth is apparent and daily as tumors reach near maximum tumor burden. Mice were euthanized by CO2 asphyxiation when total tumor burden was reached, as defined as 10% of total body weight, then perfused via the left ventricle with 5 mL PBS followed by 10 mL 4% paraformaldehyde and an additional 5 mL PBS. Tumors and various organs were dissected and either fixed in 4% paraformaldehyde prior to embedding in paraffin, or stored in PBS for no more than 1 hour before embedding in low-melt agar.
Paraffin blocks were sectioned at 10 μm thick. Sections were de-paraffinized and rehydrated in xylene and ethanol series. After antigen retrieval (antigen retrieval solution, Vector), sections were blocked with Fish Skin Gelatin/PBS (6 g/L) containing 10% of goat or horse serum for 1 hour at room temperature. An endogenous mouse IgG blocking consisting in incubation of mouse tissue sections with unconjugated Fab Fragment Goat anti-mouse IgG (H+L) (Jackson ImmunoResarch Labs) for 1 hour at room temperature were performed. Slides were incubated with the following antibodies: isolectin g5-IB4 Alexa-647 conjugate (5 μg/mL, Invitrogen), mouse monoclonal SM α-actin-Cy5 (4.4 μg/mL, Sigma Aldrich), rabbit polyclonal NG2 (5 μg/mL, Millipore) and rat monoclonal TER-119 (5 μg/mL, Santa Cruz). The secondary antibody used to detect NG2 staining was donkey anti-rabbit conjugated to Alexa-488 (5 ug/mL, Abcam); to detect TER-119 staining donkey anti-rat conjugated to Alexa-488 (5 μg/mL) was used. For blood vessel density measurements, tissues that were embedded in low-melt agar were sectioned at 50 μm thick and permeablized in Eppendorf tubes with 0.02% saponin. Sections were stained with isolectin g5-IB4, SM alpha-actin-Cy5 and NG2 as described above, then transferred to slides, counter-stained with DAPI and coverslipped for imaging.
Image acquisition and analysis
Images were acquired with Olympus BX41 fitted with a Q imaging Retiga 2000R camera. Image acquisition was performed with the Q Capture Pro software (Media Cybernetics & QImaging Inc). Settings were fixed at the beginning of both acquisition and analysis steps and were unchanged. Brightness and contrast were lightly adjusted after merging. Image analysis was performed with Image J [10, 33] using the JACoP plugin [12, 13, 34] for quantification of percent cell coverage and manual analysis for vessel density. Confocal images were acquired using a Zeiss LSM700 scanning confocal microscope with 405nm, 488nm, 555nm, and 637nm solid-state lasers. Analysis of confocal images was completed using Zeiss Zen 2009 software.
LNCaPs and C42-B4s were cultured in T-media (Gibco), supplemented with Fetal Bovine Serum (5%), and Penicillin-Streptomycin (100 U/mL, Gibco). Rat aortic SMCs were isolated and cultured as previously described [15, 35] and were cultured in growth medium (DMEM/F12, Gibco) supplemented with Fetal Bovine Serum (10%), L-glutamine (1.6 mM, Gibco) and Penicillin-Streptomycin (100 U/mL, Gibco). HUVECs were cultured on dishes coated with 0.1% gelatin in M-199 media supplemented with Fetal Bovine Serum (10%).
The XMRV clone VP62 plasmid was obtained from Dr Robert Silverman [17, 36]. The MoMLV-4070a plasmid was obtained from Dr Alan Rein [1, 14, 19]. B4rv was isolated and sequenced from the C42-B4 cell line obtained from Dr Sally Parsons (University of Virginia). All viruses were produced by transfection of 293T cells with appropriate plasmid, harvesting the culture medium 12 to 72 hours later, and filtering the medium through 0.45-μm-pore low-protein-binding filters to remove cells and debris. Viruses were stored at -80°C. Viral titers were established by infection of naïve LNCaPs plated on glass coverslips within 6-well plates with serial dilutions of viral stocks for 24 hours, followed by formalin fixation and staining for gag proteins using rabbit polyclonal gag antibody (5 μg/mL, Abcam) followed by the secondary donkey anti-rabbit conjugated to Alexa-488 (5 ug/mL, Abcam).
Construction of amphotropic/xenotropic chimera viruses
Used to generate data for figure:
3, 4, S11
3, 4, S11
3, 4, S11
3, 4, S11
MoA 5 bbone
XMRV adapt MoA
XMRV adapt MoA
MoA adapt XMRV
MoA adapt XMRV
MoA 3bbone R
XMRV 5bbone F
MoA adapt XMRV
MoA adapt XMRV
XMRV adapt MoA
XMRV 3bbone F
XMRV 3bbone R
XPR1 F 
XPR1 R 
Infection of LNCaP cells and TCM generation
LNCaP cells were seeded into 6-well plates at 2×10^4 cells per well, and the medium was replaced 1 day later. Two days after cell seeding, ~10^6 infectious units was added to each well with 10 μg/ml Polybrene to increase the infection efficiency. The medium was replaced 1 day after infection with serum free medium. Three days after infection, culture supernatant was harvested and passed through 0.45-μm-pore low-protein-binding filters to remove cells and debris and then used as TCM.
SMC marker gene expression by q-rtPCR
Rat aortic SMCs were seeded into 6-well plates at 2×104 cells per well, and allowed to adhere for 1 day. Culture media was then removed, cells were briefly washed with PBS and TCM generated from infected LNCaP cells as described above was placed in each well (2 mL per well). SMCs were cultured for another 3 days and then total RNA was isolated using the Trizol reagent (Invitrogen) according to the protocol of the manufacturer. One microgram of RNA was reverse transcribed with iScript cDNA synthesis kit (BioRad). Q-rtPCR was performed by iCycler technology (BioRad) for SMC marker genes Tagln, Myh11, Acta2 as well as the genes Mmp3 and Mmp9. Expression of genes was normalized to Gapdh levels. See Table 1 for primer sequences.
Cell migration assays were performed on Millipore MultiScreen-MIC plates with 8 μm pores. Rat aortic SMCs were grown to 70% confluence and then switched to serum-free media. A cell suspension (1×105 cells/mL, 150 μL) was added to the upper well in serum-free media containing 0.1% BSA (Sigma). TCMs from infected or uninfected LNCaPs were added to the bottom chambers. For all experiments 5 μg/ml fibronectin (Sigma) was added to the bottom chamber in serum-free media with 0.1% BSA. The chambers were incubated at 37°C in a CO2 incubator for 16 hours, and fixed in 4% formaldehyde. The cells that did not migrate (remained on top of the membrane) were removed from the upper wells and the invaded cells were stained with 0.2% Crystal Violet solution in 7% ethanol. Cells from 8–10 randomly chosen high-power fields (magnification x20) on the lower surface of the filter were counted.
HUVEC tube formation and siVEGF transfection
50 μL of Matrigel was plated in each well of a 96-well plate on ice using pre-chilled pipette tips, avoiding the generation of any bubbles. The plate was then incubated for 30 minutes at 37°C to allow the Matrigel to solidify. HUVECs were suspended at a density of 1.5x10^5 cells/mL in the TCM of infected LNCaPs generated as described above. 150 μL of HUVECs in TCM was pipetted on top of the solidified Matrigel in the 96-well plate, and the plate was incubated for 8 hours at 37°C. Endothelial tube branch points from 8–10 randomly chosen high-power fields (magnification ×20) were counted.
Values are expressed as means ± s.e.m. q-rtPCR, migration and endothelial cell tube formation experiments were performed in triplicate. Comparison between groups was tested using non-parametric ANOVA test the Statistical Analysis System (SAS, version 9.2, Cary, NC). A value of P≤0.05 was considered significant.
We would like to thank Mary E. McCanna, Rupa S. Tripathi, Melissa Bevard and Dr. Elizabeth Greene for their knowledge and technical expertise, Dr Sarah J. Parsons for providing us with the C4 cell lines, Dr Kimberly Kelly for providing a C4-2 B4 cell line, and Dr Alan Rein for providing us with MoMLV-4070a. This work was supported by NIH grants R01 HL057353, R01 HL098538, and R01 HL087867 (to GKO). Ms. Murgai is supported by the American Heart Association Predoctoral Fellowship 11POST7760009.
- Metzger MJ, Holguin CJ, Mendoza R, Miller AD: The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells. J Virol. 2010, 84: 1874-1880. 10.1128/JVI.01941-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Lombardi VC, Ruscetti FW, Gupta Das J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA: Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science. 2009, 326: 585-589. 10.1126/science.1179052.View ArticlePubMedGoogle Scholar
- Silverman RH: A scientific journey through the 2-5A/RNase L system. Cytokine Growth Factor Rev. 2007, 18: 381-388. 10.1016/j.cytogfr.2007.06.012.PubMed CentralView ArticlePubMedGoogle Scholar
- Pandhare-Dash J, Mantri CK, Gong Y, Chen Z, Dash C: XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27Kip1. Prostate. 2011, 72: 886-897.View ArticlePubMedGoogle Scholar
- Stieler K, Schumacher U, Horst AK, Fischer N: XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22rv1 cells a suitable prostate cancer model?. PLoS One. 2012, 7: e42321-10.1371/journal.pone.0042321.PubMed CentralView ArticlePubMedGoogle Scholar
- Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, Miller K, Kurth R, Bannert N: Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology. 2009, 6: 92-10.1186/1742-4690-6-92.PubMed CentralView ArticlePubMedGoogle Scholar
- Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, Hackett J, Qiu X, Luk KC, Schochetman G, Knox A, Kogelnik AM, Levy JA: No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science. 2011, 333: 94-97. 10.1126/science.1204963.View ArticlePubMedGoogle Scholar
- van Kuppeveld FJM, Jong ASD, Lanke KH, Verhaegh GW, Melchers WJG, Swanink CMA, Bleijenberg G, Netea MG, Galama JMD, van der Meer JWM: Prevalence of xenotropic murine leukaemia virus-related virus in patients with chronic fatigue syndrome in the Netherlands: retrospective analysis of samples from an established cohort. BMJ. 2010, 340: c1018-c1018. 10.1136/bmj.c1018.PubMed CentralView ArticlePubMedGoogle Scholar
- Switzer WM, Jia H, Zheng H, Tang S, Heneine W: No Association of Xenotropic Murine Leukemia Virus-Related Viruses with Prostate Cancer. PLoS One. 2011, 6: e19065-10.1371/journal.pone.0019065.PubMed CentralView ArticlePubMedGoogle Scholar
- Paprotka T, Delviks-Frankenberry KA, Cingoz O, Martinez A, Kung HJ, Tepper CG, Hu WS, Fivash MJ, Coffin JM, Pathak VK: Recombinant Origin of the Retrovirus XMRV. Science. 2011, 333: 97-101. 10.1126/science.1205292.PubMed CentralView ArticlePubMedGoogle Scholar
- Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW: LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000, 44: 91-103. 10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L. Jul 1–44(2)View ArticlePubMedGoogle Scholar
- Oakes B, Tai AK, Cingöz O, Henefield MH, Levine S, Coffin JM, Huber BT: Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology. 2010, 7: 109-10.1186/1742-4690-7-109.PubMed CentralView ArticlePubMedGoogle Scholar
- Gupta Das J, Luk K-C, Tang N, Gaughan C, Klein EA, Kandel ES, Hackett J, Silverman RH: Absence of XMRV and Closely Related Viruses in Primary Prostate Cancer Tissues Used to Derive the XMRV-Infected Cell Line 22Rv1. PLoS One. 2012, 7: e36072-10.1371/journal.pone.0036072.View ArticleGoogle Scholar
- Peredo C, O’Reilly L, Gray K, Roth MJ: Characterization of chimeras between the ecotropic Moloney murine leukemia virus and the amphotropic 4070A envelope proteins. J Virol. 1996, 70: 3142-3152.PubMed CentralPubMedGoogle Scholar
- Fishman JA, Scobie L, Takeuchi Y: Xenotransplantation-associated infectious risk: a WHO consultation. Xenotransplantation. 2012, 19: 72-81. 10.1111/j.1399-3089.2012.00693.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA: Hallmarks of Cancer: The Next Generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013.View ArticlePubMedGoogle Scholar
- Levy JA, Pincus T: Demonstration of biological activity of a murine leukemia virus of New Zealand black mice. Science. 1970, 170: 326-327. 10.1126/science.170.3955.326.View ArticlePubMedGoogle Scholar
- Xian X: Pericytes limit tumor cell metastasis. J Clin Invest. 2006, 116: 642-651. 10.1172/JCI25705.PubMed CentralView ArticlePubMedGoogle Scholar
- Kim S, Kim N, Dong B, Boren D, Lee SA, Gupta Das J, Gaughan C, Klein EA, Lee C, Silverman RH, Chow SA: Integration Site Preference of Xenotropic Murine Leukemia Virus-Related Virus, a New Human Retrovirus Associated with Prostate Cancer. J Virol. 2008, 82: 9964-9977. 10.1128/JVI.01299-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet. 2002, 33: 49-54.View ArticlePubMedGoogle Scholar
- Goel S, Wong AH-K, Jain RK: Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012, 2: a006486-10.1101/cshperspect.a006486.PubMed CentralView ArticlePubMedGoogle Scholar
- de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA: Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010, 12: 233-242. 10.1093/neuonc/nop027.PubMed CentralView ArticlePubMedGoogle Scholar
- Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 64: 3731-3736. 10.1158/0008-5472.CAN-04-0074.View ArticlePubMedGoogle Scholar
- Vaughan AE, Mendoza R, Aranda R, Battini JL, Miller AD: Xpr1 Is an Atypical G-Protein-Coupled Receptor That Mediates Xenotropic and Polytropic Murine Retrovirus Neurotoxicity. J Virol. 2012, 86: 1661-1669. 10.1128/JVI.06073-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Yan Y, Liu Q, Kozak CA: Six host range variants of the xenotropic/polytropic gammaretroviruses define determinants for entry in the XPR1 cell surface receptor. Retrovirology. 2009, 6: 87-10.1186/1742-4690-6-87.PubMed CentralView ArticlePubMedGoogle Scholar
- Setty MKHG, Devadas K, Ragupathy V, Ravichandran V, Tang S, Wood O, Gaddam DS, Lee S, Hewlett IK: XMRV: usage of receptors and potential co-receptors. Virol J. 2011, 8: 423-10.1186/1743-422X-8-423.View ArticlePubMedGoogle Scholar
- Stieler K, Fischer N: Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS One. 2010, 5: e11738-10.1371/journal.pone.0011738.PubMed CentralView ArticlePubMedGoogle Scholar
- Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, Soloviov S, Schreiber L, Matzkin H, Orr-Urtreger A: A Novel Founder Mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet. 2002, 71 (4): 981-984. 10.1086/342775.PubMed CentralView ArticlePubMedGoogle Scholar
- Hofacre A, Fan H: Jaagsiekte Sheep Retrovirus Biology and Oncogenesis. Viruses. 2010, 2: 2618-2648. 10.3390/v2122618.PubMed CentralView ArticlePubMedGoogle Scholar
- Maeda N, Fan H, Yoshikai Y: Oncogenesis by retroviruses: old and new paradigms. Rev Med Virol. 2008, 18: 387-405. 10.1002/rmv.592.View ArticlePubMedGoogle Scholar
- Stieler K, Schulz C, Lavanya M, Aepfelbacher M, Stocking C, Fischer N: Host range and cellular tropism of the human exogenous gammaretrovirus XMRV. Virology. 2010, 399: 23-30. 10.1016/j.virol.2009.12.028.View ArticlePubMedGoogle Scholar
- Groom HCT, Bishop KN: The tale of xenotropic murine leukemia virus-related virus. J Gen Virol. 2012, 93: 915-924. 10.1099/vir.0.041038-0.View ArticlePubMedGoogle Scholar
- ImageJ. http://imagej.nih.gov,
- Bolte S, Cordelières FP: A guided tour into subcellular colocalization analysis in light microscopy. J Microsc. 2006, 224: 213-232. 10.1111/j.1365-2818.2006.01706.x.View ArticlePubMedGoogle Scholar
- Geisterfer AA, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res. 1988, 62: 749-756. 10.1161/01.RES.62.4.749.View ArticlePubMedGoogle Scholar
- Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL: Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant. PLoS Pathog. 2006, 2: e25-10.1371/journal.ppat.0020025.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.